Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Anesth Pain Med ; 11(1): e112348, 2021 Feb.
Article in English | MEDLINE | ID: mdl-34221945

ABSTRACT

CONTEXT: The International Association for the Study of Pain (IASP) defines chronic pain as pain that persists or recurs for longer than 3 months. Chronic pain has a significant global disease burden with profound effects on health, quality of life, and socioeconomic costs. EVIDENCE ACQUISITION: Narrative review. RESULTS: There are several treatment options, including pharmacological therapy, physical rehabilitation, psychological therapies, and surgical interventions, for chronic pain management. Magnesium has been FDA-approved for several indications including hypomagnesemia, arrhythmia, prevention of seizures in eclampsia/preeclampsia, and constipation. Magnesium has been used for numerous off-label uses, notably for acute and chronic pain management. The mechanism of magnesium in pain management is primarily through its action as a voltage-gated antagonist of NMDA receptors, which are involved in pain transduction. CONCLUSIONS: This narrative review will focus on the current evidence and data surrounding the utilization of magnesium as a treatment option for chronic pain.

2.
Curr Pain Headache Rep ; 25(1): 6, 2021 Jan 25.
Article in English | MEDLINE | ID: mdl-33495883

ABSTRACT

PURPOSE OF REVIEW: Loin pain hematuria syndrome (LPHS) is rare and seldom diagnosed, yet it has a particularly significant impact on those affected. This is a review of the latest and seminal evidence of the pathophysiology and diagnosis of LPHS and presents the typical clinical presentation and treatment options available. RECENT FINDINGS: LPHS is typically found in young women with characteristic symptoms, including severe recurrent flank pain and gross or microscopic hematuria. The majority of patients will experience crippling pain for many years without effective therapy, often requiring frequent use of narcotic medication. However, the lack of conclusive pathophysiology, in conjunction with the rarity of LPHS, has prohibited the development and trial of definitive treatment options. Nevertheless, in order to combat this rare but severe disease, management strategies have continued to evolve, ranging from conservative measures to invasive procedures. This review presents an overview of the current hypotheses on the pathophysiology of LPHS in addition to summarizing the management strategies that have been utilized. Only 30% of LPHS patients will experience spontaneous resolution, whereas the majority will continue to face chronic, crippling pain. Several methods of treatment, including invasive and non-invasive, may provide an improved outcome to these patients. Treatment should be individually tailored and multi-disciplinary in nature. Further research is required to further elucidate the pathophysiology and develop new, specific, treatment options.


Subject(s)
Flank Pain/therapy , Hematuria/therapy , Age Distribution , Analgesics, Opioid/therapeutic use , Anesthetics, Local/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Bupivacaine/administration & dosage , Capsaicin/administration & dosage , Denervation , Electric Stimulation Therapy , Flank Pain/complications , Flank Pain/epidemiology , Flank Pain/physiopathology , Ganglia, Spinal , Hematuria/complications , Hematuria/epidemiology , Hematuria/physiopathology , Humans , Hypnosis , Infusions, Spinal , Kidney/innervation , Nephrectomy , Neuromuscular Agents/therapeutic use , Pulsed Radiofrequency Treatment , Renal Dialysis , Sensory System Agents/administration & dosage , Sex Distribution , Splanchnic Nerves , Sympathectomy , Syndrome , Transplantation, Autologous , Ureter
3.
Surg Infect (Larchmt) ; 18(7): 793-798, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28850295

ABSTRACT

BACKGROUND: Necrotizing soft-tissue infections (NSTIs) result in significant morbidity and mortality rates, with as many as 76% of patients dying during their index admission. Published data suggest NSTIs rarely involve fungal infections in immunocompetent patients. However, because of the recent recognition of fungal infections in our population, we hypothesized that such infections frequently complicate NSTIs and are associated with higher morbidity and mortality rates. METHODS: A prospectively maintained Acute and Critical Care Surgery (ACCS) database spanning 2008-2015 and including more than 7,000 patients was queried for patients with NSTIs. Microbiologic data, demographics, and clinical outcomes were abstracted. Risk factors and outcomes associated with NSTI with positive intra-operative fungal cultures were determined. Frequencies were compared by χ2 and continuous variables by the Student t-test using SPSS. Because the study included only archived data, no patient permission was needed. RESULTS: A total of 230 patients were found to have NSTIs; 197 had intra-operative cultures, and 21 (10.7%) of these were positive for fungi. Fungal infection was more common in women, patients with higher body mass index (BMI), and patients who had had prior abdominal procedures. There were no significant differences in demographics, co-morbidities, or site of infection. The majority of patients (85.7%) had mixed bacterial and fungal infections; in the remaining patients, fungi were the only species isolated. Most fungal cultures were collected within 48 h of hospital admission, suggesting that the infections were not hospital acquired. Patients with positive fungal cultures required two more surgical interventions and had a three-fold greater mortality rate than patients without fungal infections. CONCLUSIONS: This is the largest series to date describing the impact of fungal infection in NSTIs. Our data demonstrate a three-fold increase in the mortality rate and the need for two additional operations. Consideration should be given to starting patients on empiric anti-fungal therapy in certain circumstances.


Subject(s)
Fasciitis, Necrotizing/mortality , Mycoses/mortality , Soft Tissue Infections/mortality , Adult , Aged , Body Mass Index , Fasciitis, Necrotizing/epidemiology , Fasciitis, Necrotizing/microbiology , Female , Humans , Length of Stay , Male , Middle Aged , Mycoses/epidemiology , Mycoses/microbiology , Prospective Studies , Risk Factors , Soft Tissue Infections/epidemiology , Soft Tissue Infections/microbiology
SELECTION OF CITATIONS
SEARCH DETAIL
...